NRBC Bank and OXFAM, Bangladesh will work together for welfare of the marginal people through micro credit, creating cashless village facility and  online marketplace for small entrepreneurs. NRBC Bank and OXFAM signed a memorandum of understanding (MoU) in this regard on Monday. Golam Awlia, Managing Director and CEO of NRBC Bank and Ashish Damle, Country Director, OXFAM, Bangladesh signed the MoU on behalf of their respective sides. Also read: WFP, Oxfam, Green Delta Insurance join hands to protect labourers The objective of the project is to alleviate poverty and injustice and create scope for them up with fourth industrial revelation by ensuring their access to financial and technological ecosystems. Kazi Md. Talha, Additional Managing Director, Kabir Ahmed, DMD, Harunur Rashid, CFO, Kazi Safayet Kabir, Head of FI, Mohammad Soeb Iftekhar, head of economic inclusion & Justice, Sonia Tahera Kabir, business development manager of OXFAM, Bangladesh were among others, present at the function. Also read: ACC signs MoU with Oxfam to strengthen anti-graft activities

Bangladesh has ranked 113 on the Commitment to Reducing Inequality (CRII) Index 2020.

The United Nations World Food Programme (WFP), Oxfam Bangladesh and Green Delta Insurance Company Ltd have launched a new insurance scheme to protect casual agricultural labourers in Bangladesh from floods during this monsoon.

Oxfam has urged governments and pharmaceutical companies to guarantee that vaccines, tests, and treatments will be patent-free and equitably distributed to all nations and people.    The agency made the call on Thursday, ahead of the World Health Assembly next week. The virtual meeting on Monday will be attended by health ministers from 194 countries.   Vaccinating the poorest half of humanity – 3.7 billion people - could cost less than the 10 biggest pharmaceutical companies make in four months, Oxfam said on Thursday.    The Gates Foundation has estimated that the cost of procuring and delivering a safe and effective vaccine to the world’s poorest people is $25 billion.    Last year, the top ten pharmaceutical companies made $89 billion in profits – an average of just under $30 billion every four months.   Oxfam warned that rich countries and huge pharmaceutical companies – driven by national or private interests – could prevent or delay the vaccine from reaching vulnerable people, especially those living in developing countries.   The EU has proposed the voluntary pooling of patents for coronavirus vaccines, treatments, and tests in their draft resolution for the World Health Assembly.    If made mandatory and worldwide, this would ensure that all countries could produce, or import low cost versions, of any available vaccines, treatments, and tests.    Leaked Documents    Oxfam said leaked documents reveal that the Trump administration is trying to delete references to pooled patents and insert strong language on respecting the patents of the pharmaceutical industry.    This would give pharmaceutical companies exclusive rights to produce, and set prices for any vaccines, treatments and tests they develop – even if taxpayer money has been used to fund their research and development.    Jose Maria Vera, Oxfam International Interim Executive Director, said providing a vaccine to 3.7 billion people could cost less than what the ten biggest pharmaceutical companies make in four months.    Anything less than guaranteeing that a vaccine is made available free of charge to all people would be obscene.    “Vaccines, tests and treatments should be distributed according to need, not auctioned off to the highest bidder. We need safe, patent-free vaccines, treatments and tests that can be mass produced worldwide, and a clear and fair plan for how they will be distributed.”   Once vaccines or treatments are developed, there is also a high risk that rich and powerful governments will outbid poorer nations and force their way to the front of the queue, as they did in the scramble for other essential medical supplies such as personal protective equipment and oxygen.    In March, drug manufacturer Gilead moved to extend the monopoly on a potential treatment for the virus, and only withdrew it after a public outcry.    Gilead has now donated a significant portion of its current supply of remdesivir to the US government, but news reports suggest the company could make significant profits from subsequent production.    Some Wall Street analysts expect Gilead to charge more than $4,000 per patient for the drug, even though the cost of remdesivir can be as low as $9 per patient.   Poor Countries   Many poor countries are unable to access essential vaccines and medicines due to patent rules which give pharmaceutical companies monopoly rights and the power to set prices well above what they can afford.    Pneumonia is the biggest killer of children under the age of five, with 2,000 children dying every day. For over a decade, millions of children have not had access to patented pneumonia vaccines manufactured by Pfizer and GlaxoSmithKline due to its high cost.    After years of campaigning by Médecins San Frontieres, both companies reduced their prices in 2016, but only for the very poorest countries, leaving millions of children still without access to their vaccine.   Oxfam is proposing a four-point global plan that calls for:   a)    Mandatory sharing of all Covid-19 related knowledge, data and intellectual property, and a commitment to make all public funding conditional on treatments or vaccines being made patent-free and accessible to all.   b)   A commitment to deliver additional global vaccine manufacturing and distribution capacity with funding from rich country governments.    This means building factories in countries willing to share and investing now in the millions of additional health workers needed to deliver prevention, treatment, and care both now and in the future.   c)    A globally agreed, equitable distribution plan with a locked-in fairness formula so that supply is based on need, not ability to pay.    Vaccines, treatments, and tests should be produced and supplied at the lowest cost possible to governments and agencies, ideally no more than $2 a dose for a vaccine, and provided free at the point of delivery to everyone that needs it.    d)   A commitment to fix the broken system for the research and development of new medicines. The current system puts pharmaceutical profit above the health of people across the world meaning many needed put unprofitable medicines never get developed, and those that do are too often priced out of reach for the poorest countries and people.   Vera said, “Delivering an affordable vaccine for everyone will require unprecedented global cooperation. Governments must rip up the rulebook and prioritise the health of people everywhere, over the patents and profits of pharmaceutical corporations. Governments must ensure that no one is left behind.”    The Gates Foundation estimated the cost of producing and distributing a vaccine and has confirmed that this cost relates to the production and distribution in low and lower middle income countries only.   Oxfam believes that vaccines should ideally be produced and supplied for no more than $2 per dose.    This is a reasonable challenge to set given that new complex vaccines for big killers like pneumonia are already available for this price.

Eighteen humanitarian agencies called on governments in the region to save lives of stranded asylum seekers in the Bay of Bengal and Andaman Sea.

International agency Oxfam and the Anti-Corruption Commission (ACC) have signed a Memorandum of Understanding (MoU), aiming to strengthen anti-corruption activities in the country.